Medivation News - MDV

Medivation Common Stock Begins Trading on Nasdaq Global Market Under the Symbol 'MDVN'

SAN FRANCISCO, March 20 /PRNewswire-FirstCall/ -- Medivation, Inc. (NASDAQ:MDVN) today announced that its common stock will begin trading on The...

Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Dise

SAN FRANCISCO, March 19 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that six-month results from its randomized...

Dutton Associates Announces Investment Opinion: Medivation Strong Speculative Buy Rating In Update Coverage By Dutton Associates

Dutton Associates continues its coverage of Medivation Inc. (AMEX:MDV) reiterating a Strong Speculative Buy rating and a $27.00...

Medivation Common Stock Approved for Listing on the Nasdaq Global Market

SAN FRANCISCO, March 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that The Nasdaq Listing Qualifications Department...

Medivation to Present at Cowen and Company's 27th Annual Healthcare Conference

SAN FRANCISCO, March 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief...

Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer

- Data Presented in Oral and Poster Presentations at ASCO's Prostate Cancer Symposium - SAN FRANCISCO, Feb. 26 /PRNewswire-FirstCall/...

Preclinical Efficacy Data on Medivation's MDV3100 to Be Presented at ASCO-sponsored Prostate Cancer Symposium

SAN FRANCISCO, Feb. 16 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that preclinical efficacy data on MDV3100, a novel...

Medivation to Present at BIO CEO & Investor Conference 2007

SAN FRANCISCO, Feb. 5 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that David Hung, M.D., president and chief executive...

Medivation's Dimebon(TM) Phase 2 Trial Results to be Presented at 8th International Conference on Alzheimer's and Parkinson's Di

SAN FRANCISCO, Jan. 30 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that results of its Phase 2 efficacy study of...

Medivation Names Lisa Taylor Vice President of Commercial Development

SAN FRANCISCO, Jan. 17 /PRNewswire/ -- Medivation, Inc. (AMEX:MDV) today announced that it has appointed Lisa Taylor as vice president of...

Dutton Associates Announces Investment Opinion: Medivation Strong Speculative Buy Rating in Update Coverage by Dutton Associates

Dutton Associates continues its coverage of Medivation Inc. (AMEX:MDV) reiterating a Strong Speculative Buy rating and a $22.00...

Medivation to Host Conference Call on November 15 to Provide Clinical Development Update for Lead Product Candidate Dimebon(TM)

SAN FRANCISCO, Nov. 8 /PRNewswire-FirstCall/ -- Medivation, Inc. (AMEX:MDV) today announced that it will hold a conference call to provide an...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medivation (MDV)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MDV News

Medivation Common Stock Begins Trading on Nasdaq Global Market Under the Symbol 'MDVN'

Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Dise

Dutton Associates Announces Investment Opinion: Medivation Strong Speculative Buy Rating In Update Coverage By Dutton Associates

Medivation Common Stock Approved for Listing on the Nasdaq Global Market

Medivation to Present at Cowen and Company's 27th Annual Healthcare Conference

Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer

Preclinical Efficacy Data on Medivation's MDV3100 to Be Presented at ASCO-sponsored Prostate Cancer Symposium

Medivation to Present at BIO CEO & Investor Conference 2007

Medivation's Dimebon(TM) Phase 2 Trial Results to be Presented at 8th International Conference on Alzheimer's and Parkinson's Di

Medivation Names Lisa Taylor Vice President of Commercial Development

Dutton Associates Announces Investment Opinion: Medivation Strong Speculative Buy Rating in Update Coverage by Dutton Associates

Medivation Appoints Sue Wollowitz, Ph.D., Vice President of Chemistry and Manufacturing

Medivation, Inc. Adopts Shareholder Rights Plan

Medivation Provides Clinical Development Update for Its Three Programs

Medivation to Host Conference Call on November 15 to Provide Clinical Development Update for Lead Product Candidate Dimebon(TM)

MDV Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Medivation (MDV) News

Medivation (MDV)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

MDV News

Medivation Common Stock Begins Trading on Nasdaq Global Market Under the Symbol 'MDVN'

Medivation Announces Presentation of Full Top-Line Data From Dimebon(TM) Six-Month Trial at Major International Alzheimer's Dise

Dutton Associates Announces Investment Opinion: Medivation Strong Speculative Buy Rating In Update Coverage By Dutton Associates

Medivation Common Stock Approved for Listing on the Nasdaq Global Market

Medivation to Present at Cowen and Company's 27th Annual Healthcare Conference

Medivation's MDV3100 Shown to Be Effective in a Preclinical Model of Hormone-Refractory Prostate Cancer

Preclinical Efficacy Data on Medivation's MDV3100 to Be Presented at ASCO-sponsored Prostate Cancer Symposium

Medivation to Present at BIO CEO & Investor Conference 2007

Medivation's Dimebon(TM) Phase 2 Trial Results to be Presented at 8th International Conference on Alzheimer's and Parkinson's Di

Medivation Names Lisa Taylor Vice President of Commercial Development

Dutton Associates Announces Investment Opinion: Medivation Strong Speculative Buy Rating in Update Coverage by Dutton Associates

Medivation Appoints Sue Wollowitz, Ph.D., Vice President of Chemistry and Manufacturing

Medivation, Inc. Adopts Shareholder Rights Plan

Medivation Provides Clinical Development Update for Its Three Programs

Medivation to Host Conference Call on November 15 to Provide Clinical Development Update for Lead Product Candidate Dimebon(TM)

MDV Discussion

Your Recent History